Brief: Glaxosmithkline Pharmaceuticals Receives TDS Demand Liability Of 20.1 Million Rupees
31/03/2026 14:02
March 31 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS: GLAXOSMITHKLINE PHARMACEUTICALS LTD - RECEIVES TDS DEMAND LIABILITY OF 20.1 MILLION RUPEES Source text: ID:nBSEbNrKqt Further company coverage: GLAX.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GlaxoSmithKline Pharmaceuticals
See all newsIndia's GlaxoSmithKline Pharma gains after Q4 profit rise; PT hike
Brief: Glaxosmithkline Pharmaceuticals March-Quarter Consol Profit 2.78 Billion Rupees
India's Cipla jumps on FDA approval for Ventolin HFA generic inhaler
Brief: Glaxosmithkline Pharmaceuticals Receives TDS Demand Liability Of 20.1 Million Rupees
Brief: Glaxosmithkline Pharmaceuticals Ltd Receives Final Order With Tax Demand Liability Of 232.1 Mln Rupees For AY 2023-24